The European research-based pharmaceutical industry’s commitment to tackling the coronavirus pandemic

EFPIA is the voice of the research-based pharmaceutical industry in Europe. As an industry #WeWontRest in fighting the COVID-19 pandemic.

Our first thoughts are with all those affected by the coronavirus pandemic. We are committed to working collaboratively across the research and healthcare communities, utilising our world-leading science, people and resources to tackle this outbreak.

Our aims in this time of public health crisis are to:

- Ensure the safe supply of medicines to the patients that need them
- Research and develop new vaccines, diagnostics and treatments for use in the fight against COVID-19
- Partner and support organisations on the ground to fight against COVID-19

WE ARE DOING THIS BY:

- Rapidly screening our vast global libraries of medicines to identify potential treatments and have numerous clinical trials underway to test new and existing therapies.
- Bringing together the best scientists from industry and academia through the Innovative Medicines Initiative to accelerate the development of new diagnostics and treatments.
- Establishing a direct link between manufacturers and EMA & Heads of Medicines Agencies to provide constant information about stock, manufacturing capacity and market tensions in order to anticipate and pro-actively address any potential disruptions or shortages.
- Continuously monitoring our supply chains and working to ensure the supply of medicines to the patients that need them.
- Working with the European Institutions, Member States, public health partners, the research community, healthcare professionals and other partners to fight the spread of COVID-19.
- Launching clinical development of potential vaccines against the corona virus.
- Sharing the learnings from clinical trials in real time with governments and other companies to advance the development of new therapies.
- Expanding our manufacturing capabilities and sharing available capacity to ramp up production once a successful medicine or vaccine is developed.
- Coordinating with governments and diagnostic partners to increase COVID-19 testing capability and capacity.
- Providing financial support and in-kind donations to organisations at the front line across Europe and beyond.
- Working with governments and health systems to ensure that when new treatments and vaccines are approved they are available and affordable.
- Protecting our workforce and the communities where we live and work, having employees working from home whenever possible.